Alkermes (ALKS) Stock: Buy, Sell, or Hold?
ALKS - Alkermes Inc. plc
$41.75
1.21 (2.98%)
▲
5d:
+2.2%
30d:
-12.51%
90d:
-24.28%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
23d
Get Alerted When ALKS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALKS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ALKS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$78.17
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.54
14.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALKS is currently trading at $41.75, which is considered oversold relative to its 30-day fair value range of $42.10 to $47.87. The stock's valuation (Forward PE: 23.1) is in line with its historical norms (22.2). At these levels, the market is pricing in 1.3% annual earnings growth.
Technical Outlook: Technically, ALKS is in a uptrend. Immediate support is located at $39.84, while resistance sits at $44.79.
Market Sentiment: ALKS scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $56.56 (+35.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALKS is in a uptrend. Immediate support is located at $39.84, while resistance sits at $44.79.
Market Sentiment: ALKS scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $56.56 (+35.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$42.10 -
$47.87
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
93.8%
Protect Your Profits
Holding ALKS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (85/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.5% below Wall St target ($56.56)
- BULLISH: Expecting earnings turnaround to 1.3% growth with 27.0% revenue growth
- CAUTION: Bottoming setup, but lagging the sector by 25% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$42.10 -
$47.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$39.84
Resistance Level
$44.79
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$56.56
(+35.5%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
-99.4%
Profit Margin
4.0%
Valuation Premium vs History
+1.3% premium
PE vs Historical
23.1 vs 22.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$42.29
(+1%)
2-Year Target
$42.84
(+3%)
3-Year Target
$43.40
(+4%)
3-Yr Target (if PE normalizes)
(PE: 23→22)
PE COMPRESSION
$41.73
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.1, Growth: 41.8%)
$119.14
(+185%)
Base:
(SPY PE: 20.4, Growth: 41.8%)
$105.27
(+152%)
Bear:
(PE: 17.3, Growth: 41.8%)
$89.48
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (133x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Forward PE: 133.33 | Forward EPS (Implied): $0.31
Bull Case
$50.41
(+21%)
Analyst growth 15.0%, PE expands to 140.0
Base Case
$41.75
(0%)
Market implied 0.0%, PE stable at 133.3
Bear Case
$31.94
(-24%)
Severe decline -15.0%, PE contracts to 120.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 7:36 AM ET
Data refreshes hourly during market hours. Next update: 8:36 AM
Data refreshes hourly during market hours. Next update: 8:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALKS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ALKS is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced ALKS Option Strategies
Professional options setups generated by AI based on today's ALKS price and gamma walls.
